 |
Preeclampsia Diagnostics Market
Preeclampsia is a leading cause of disease and mortality among pregnant women and their kids around the world.
Preeclampsia is a type of high blood pressure that affects some women after the 20th week of pregnancy or shortly after delivery.
Up to 5% of all pregnancies are affected by this serious pregnancy condition.
In both industrialized and developing countries, it is one of the most common hypertension diseases of pregnancy.
If not detected early, it can lead to preterm birth and other issues such as organ failure, seizures, or eclampsia, as well as death.
During the forecast period, the rising prevalence of preeclampsia is expected to boost the market growth.
The necessity for early detection of preeclampsia among pregnant women is predicted to increase due to rising perinatal and maternal morbidity and death rates, which is expected to drive the global preeclampsia diagnostics market growth over the forecast period.
Increasing preeclampsia product launches are likely to drive market growth over the forecast period.
During the projection period, prominent players are expected to develop more new products, boosting the market growth.
The Impact of Coronavirus on the Global Preeclampsia Diagnostics Market (COVID-19)
Pandemic
The COVID-19 virus has spread to over 100 nations since its outbreak in December 2019, prompting the World Health Organization to designate it as a public health emergency.
Key Players
Major players operating in the global preeclampsia diagnostics market are Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, Miraculins Inc.
0 Comments